Patient initiation and maintenance of GLP-1 RAs for treatment of obesity

References

• Obesity Collaborators GBD, Afshin A, Forouzanfar MH, et al. Health effects of overweight and obesity in 195 countries over 25 years. N Engl J Med. 2017;377(1):13–27.
   PubMed Web of Science ®Google Scholar
• Church TS, Kuk JL, Ross R, et al. Association of cardiorespiratory fitness, body mass index, and waist circumference to nonalcoholic fatty liver disease. Gastroenterology. 2006;130(7):2023–2030. .
   PubMed Web of Science ®Google Scholar
• Guh DP, Zhang W, Bansback N, et al. The incidence of co-morbidities related to obesity and overweight: a systematic review and meta-analysis. BMC Public Health. 2009;9(1):88. .
   PubMed Web of Science ®Google Scholar
• Li C, Ford ES, Zhao G, et al. Prevalence of self-reported clinically diagnosed sleep apnea according to obesity status in men and women: National Health and Nutrition Examination Survey, 2005-2006. Prev Med. 2010;51(1):18–23. .
   PubMed Web of Science ®Google Scholar
• Caterson ID, Hubbard V, Bray GA, et al. Prevention conference VII: obesity, a worldwide epidemic related to heart disease and stroke: group III: worldwide comorbidities of obesity. Circulation. 2004;110(18):e476–83. .
   PubMed Web of Science ®Google Scholar
• Yumuk V, Tsigos C, Fried M, et al. European guidelines for obesity management in adults. Obes Facts. 2015;8(6):402–424. .
   PubMed Web of Science ®Google Scholar
• Alford S, Patel D, Perakakis N, et al. Obesity as a risk factor for Alzheimer’s disease: weighing the evidence. Obes Rev. 2018;19(2):269–280. .
   PubMed Web of Science ®Google Scholar
• Garvey WT, Mechanick JI, Brett EM, et al. AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS AND AMERICAN COLLEGE OF ENDOCRINOLOGY COMPREHENSIVE CLINICAL PRACTICE GUIDELINES FOR MEDICAL CARE OF PATIENTS WITH OBESITY. Endocr Pract. 2016;22(Suppl):31–203.
   Google Scholar
• Kolb R, Sutterwala FS, Zhang W. Obesity and cancer: inflammation bridges the two. Curr Opin Pharmacol. 2016;2977–2989.
   Web of Science ®Google Scholar
• American Medical Association. 2012 Resolutions 2012. [cited 2021 Jun 30]. Available from: https://www.ama-assn.org/sites/ama-assn.org/files/corp/media-browser/public/hod/a12-resolutions_0.pdf
   Google Scholar
• Bray GA, Kim KK, Wilding JPH. Obesity: a chronic relapsing progressive disease process. A position statement of the World Obesity Federation. Obes Rev. 2017;18(7):715–723.
   PubMed Web of Science ®Google Scholar
• European Association for the Study of Obesity. 2015 Milan Declaration: a Call to Action on Obesity 2015. [cited 2021 Jun 30]. Available from: https://cdn.easo.org/wp-content/uploads/2018/12/16195534/EASO-Milan-Declaration-FINAL.pdf
   Google Scholar
• European Medicines Agency. Guideline on clinical evaluation of medicinal products used in weight management 2014. [cited 2021 Jun 30]. Available from: https://www.ema.europa.eu/en/documents/scientific-guideline/guideline-clinical-evaluation-medicinal-products-used-weight-management-revision-1_en.pdf
   Google Scholar
• Obesity Canada. Obesity in Canada Accessed 14th November 2019. [cited 2021 Jun 30]. Available from: https://obesitycanada.ca/obesity-in-Canada/
   Google Scholar
• Kaplan LM, Golden A, Jinnett K, et al. Perceptions of barriers to effective obesity care: results from the National ACTION study. Obesity. 2018;26(1):61–69. .
   PubMed Web of Science ®Google Scholar
• World Health Organization. 2020 [ cited 2021 Jun 30]. Available from: https://www.who.int/topics/obesity/en/
   Google Scholar
• Apovian CM, Garvey WT, Ryan DH. Challenging obesity: patient, provider, and expert perspectives on the roles of available and emerging nonsurgical therapies. Obesity. 2015;23(Suppl 2(0 2)):S1–S26.
   Web of Science ®Google Scholar
• Jensen MD, Ryan DH, Apovian CM, et al. 2013 AHA/ACC/TOS guideline for the management of overweight and obesity in adults: a report of the American College of Cardiology/American Heart Association task force on practice guidelines and the obesity society. Circulation. 2014;129(25 Suppl 2):S102–38. .
   PubMed Web of Science ®Google Scholar
• World Health Organization. Obesity: preventing and managing the global epidemic: report of a WHO consultation. WHO Technical Report Series 8941999.
   Google Scholar
• Endocrine Society. Endocrine Society Clinical Practice Guidelines 2020 [cited 2021 Jun 30]. Available from: https://www.endocrine.org/clinical-practice-guidelines
   Google Scholar
• Bays HEMW, Christensen S, Wells S, et al. Obesity algorithm eBook, presented by the obesity medicine association. www.obesityalgorithm.org. 2019.: Obesity Medicine Association; 2021. [cited 2021 Jun 30]. Available from: https://obesitymedicine.org/obesity-algorithm/.
   Google Scholar
• Varkevisser RDM, van Stralen MM, Kroeze W, et al. Determinants of weight loss maintenance: a systematic review. Obes Rev. 2019;20(2):171–211.
   PubMed Web of Science ®Google Scholar
• Gasoyan H, Tajeu G, Halpern MT, et al. Reasons for underutilization of bariatric surgery: the role of insurance benefit design. Surg Obes Relat Dis. 2019;15(1):146–151.
   PubMed Web of Science ®Google Scholar
• Love KM, Mehaffey JH, Safavian D, et al. Bariatric surgery insurance requirements independently predict surgery dropout. Surg Obes Relat Dis. 2017;13(5):871–876.
   PubMed Web of Science ®Google Scholar
• Imbus JR, Voils CI, Funk LM. Bariatric surgery barriers: a review using Andersen’s Model of health services use. Surg Obes Relat Dis. 2018;14(3):404–412.
   PubMed Web of Science ®Google Scholar
• González-Muniesa P, Mártinez-González M-A, Hu FB, et al. Obesity. Nat Rev Dis Primers. 2017;3(1):17034.
   PubMedGoogle Scholar
• Patel D. Pharmacotherapy for the management of obesity. Metabolism. 2015;64(11):1376–1385.
   PubMed Web of Science ®Google Scholar
• Berthoud H-R. Metabolic and hedonic drives in the neural control of appetite: who is the boss? Curr Opin Neurobiol. 2011;21(6):888–896.
   PubMed Web of Science ®Google Scholar
• Cooke D, Bloom S. The obesity pipeline: current strategies in the development of anti-obesity drugs. Nat Rev Drug Discov. 2006;5(11):919–931.
   PubMed Web of Science ®Google Scholar
• Simpson KA, Martin NM, Bloom SR. Hypothalamic regulation of appetite. Expert Rev Endocrinol Metab. 2008;3(5):577–592.
   PubMedGoogle Scholar
• Hall KD, Hammond RA, Rahmandad H. Dynamic interplay among homeostatic, hedonic, and cognitive feedback circuits regulating body weight. Am J Public Health. 2014;104(7):1169–1175.
   PubMed Web of Science ®Google Scholar
• Mojsov S, Heinrich G, Wilson IB, et al. Preproglucagon gene expression in pancreas and intestine diversifies at the level of post-translational processing. J Biol Chem. 1986;261(25):11880–11889.
   PubMed Web of Science ®Google Scholar
• Kreymann B, Williams G, Ghatei MA, et al. Glucagon-like peptide-1 7-36: a physiological incretin in man. Lancet. 1987;2(8571):1300–1304.
   PubMed Web of Science ®Google Scholar
• Merchenthaler I, Lane M, Shughrue P. Distribution of pre-pro-glucagon and glucagon-like peptide-1 receptor messenger RNAs in the rat central nervous system. J Comp Neurol. 1999;403(2):261–280.
   PubMed Web of Science ®Google Scholar
• Pyke C, Heller RS, Kirk RK, et al. GLP-1 receptor localization in monkey and human tissue: novel distribution revealed with extensively validated monoclonal antibody. Endocrinology. 2014;155(4):1280–1290. .
   PubMed Web of Science ®Google Scholar
• Meier JJ. GLP-1 receptor agonists for individualized treatment of type 2 diabetes mellitus. Nat Rev Endocrinol. 2012;8(12):728–742.
   PubMed Web of Science ®Google Scholar
• Nauck MA, Heimesaat MM, Behle K, et al. Effects of glucagon-like peptide 1 on counterregulatory hormone responses, cognitive functions, and insulin secretion during hyperinsulinemic, stepped hypoglycemic clamp experiments in healthy volunteers. J Clin Endocrinol Metab. 2002;87(3):1239–1246. .
   PubMed Web of Science ®Google Scholar
• Nauck MA, Kleine N, �rskov C, et al. Normalization of fasting hyperglycaemia by exogenous glucagon-like peptide 1 (7-36 amide) in type 2 (non-insulin-dependent) diabetic patients. Diabetologia. 1993;36(8):741–744. .
   PubMed Web of Science ®Google Scholar
• Flint A, Raben A, Astrup A, et al. Glucagon-like peptide 1 promotes satiety and suppresses energy intake in humans. J Clin Invest. 1998;101(3):515–520. .
   PubMed Web of Science ®Google Scholar
• Krieger JP. Intestinal glucagon-like peptide-1 effects on food intake: physiological relevance and emerging mechanisms. Peptides. 2020;131:170342.
   PubMed Web of Science ®Google Scholar
• Hutch CR, Sandoval D. The role of GLP-1 in the metabolic success of bariatric surgery. Endocrinology. 2017;158(12):4139–4151.
   PubMed Web of Science ®Google Scholar
• Knudsen LB, Lau J. The discovery and development of liraglutide and semaglutide. Front Endocrinol (Lausanne). 2019;10:155.
   PubMed Web of Science ®Google Scholar
• AstraZeneca. Byetta® (exenatide) injection, Prescribing Information. [cited 2021 Jun 30]. Available from: http://www.accessdata.fda.gov/drugsatfda_docs/label/2009/021773s9s11s18s22s25lbl.pdf
   Google Scholar
• AstraZeneca. Bydureon (exenatide injection), Prescribing Information 2012 2017 Aug 4. https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/022200s000lbl.pdf
   Google Scholar
• Eli Lilly and Company. Trulicity (dulaglutide), Prescribing Information [cited 2021 Jun 30]. http://pi.lilly.com/ca/trulicity-ca-pm.pdf
   Google Scholar
• Novo Nordisk. Ozempic semaglutide injection - Prescibing Information. [cited 2021 Jun 30]. Available from:https://www.novo-pi.com/ozempic.pdf2019
   Google Scholar
• Novo Nordisk. Rybelsus - Prescribing Information [cited 2021 Jun 30]. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/213051s000lbl.pdf2019
   Google Scholar
• Novo Nordisk AS. Victoza (liraglutide), Prescribing Information. [cited 2021 Jun 30]. Available from: https://www.novo-pi.com/victoza.pdf.
   Google Scholar
• Sanofi-Aventis US. Adlyxin (lixisenatide), Prescribing Information[cited 2021 Jun 30]. Available from: http://www.accessdata.fda.gov/drugsatfda_docs/label/2016/208471Orig1s000lbl.pdf
   Google Scholar
• Madsbad S. Review of head-to-head comparisons of glucagon-like peptide-1 receptor agonists. Diabetes Obes Metab. 2016;18(4):317–332.
   PubMed Web of Science ®Google Scholar
• Secher A, Jelsing J, Baquero AF, et al. The arcuate nucleus mediates GLP-1 receptor agonist liraglutide-dependent weight loss. J Clin Invest. 2014;124(10):4473–4488.
   PubMed Web of Science ®Google Scholar
• Novo Nordisk. Saxenda Summary of Product Characteristics 2015 [ cited 2021 Jun 30]. Available from: https://www.ema.europa.eu/en/medicines/human/EPAR/saxenda
   Google Scholar
• Nordisk N. Saxenda Product Information: australia [ cited 2021 Jun 30]. Available from: https://www.ebs.tga.gov.au/ebs/picmi/picmirepository.nsf/pdf?OpenAgent&id=CP-2016-PI-01008-1&d=202001281016933
   Google Scholar
• *Novo Nordisk. SAXENDA (liraglutide) Prescribing Information 2020. [cited 2021 Jun 30]. Available from: https://www.novo-pi.com/saxenda.pdf.
   Google Scholar
• Astrup A, Rossner S, Van Gaal L, et al. Effects of liraglutide in the treatment of obesity: a randomised, double-blind, placebo-controlled study. Lancet. 2009;374(9701):1606–1616.
   PubMed Web of Science ®Google Scholar
• **Blackman A, Foster GD, Zammit G, et al., Effect of liraglutide 3.0 mg in individuals with obesity and moderate or severe obstructive sleep apnea: the SCALE sleep apnea randomized clinical trial. Int J Obes (Lond). 2016.40(8):1310–1319.
   PubMed Web of Science ®Google Scholar
• **Davies MJ, Bergenstal R, Bode B, et al., Efficacy of liraglutide for weight loss among patients with type 2 diabetes: the SCALE diabetes randomized clinical trial. JAMA. 314(7): 687–699. 2015.
   PubMed Web of Science ®Google Scholar
• **le Roux CW, Astrup A, Fujioka K, et al., 3 years of liraglutide versus placebo for type 2 diabetes risk reduction and weight management in individuals with prediabetes: a randomised, double-blind trial. Lancet. 389(10077): 1399–1409. 2017.
   PubMed Web of Science ®Google Scholar
• **Pi-Sunyer X, Astrup A, Fujioka K, et al., A randomized, controlled trial of 3.0 mg of liraglutide in weight management. N Engl J Med. 373(1): 11–22. 2015.
   PubMed Web of Science ®Google Scholar
• **Wadden TA, Hollander P, Klein S, et al., Weight maintenance and additional weight loss with liraglutide after low-calorie-diet-induced weight loss: the SCALE Maintenance randomized study. Int J Obes (Lond). 37(11): 1443–1451. 2013.
   PubMed Web of Science ®Google Scholar
• Wadden TA, Tronieri JS, Sugimoto D, et al. Liraglutide 3.0 mg and Intensive Behavioral Therapy (IBT) for obesity in primary care: the SCALE IBT randomized controlled trial. Obesity (Silver Spring). 2020;28(3):529–536.
   PubMed Web of Science ®Google Scholar
• Garvey WT, Birkenfeld AL, Dicker D, et al. Efficacy and safety of Liraglutide 3.0 mg in individuals with overweight or obesity and type 2 diabetes treated with basal Insulin: the SCALE Insulin randomized controlled trial. Diabetes Care. 2020;43(5):1085–1093.
   PubMed Web of Science ®Google Scholar
• Wadden TA, Walsh OA, Berkowitz RI, et al. Intensive behavioral therapy for obesity combined with liraglutide 3.0 mg: a randomized controlled trial. Obesity (Silver Spring). 2019;27(1):75–86.
   PubMed Web of Science ®Google Scholar
• Rondanelli M, Perna S, Astrone P, et al. Twenty-four-week effects of liraglutide on body composition, adherence to appetite, and lipid profile in overweight and obese patients with type 2 diabetes mellitus. Patient Prefer Adherence. 2016;10407–10413.
   Web of Science ®Google Scholar
• Floras JS. Sleep Apnea and cardiovascular disease: an enigmatic risk factor. Circ Res. 2018;122(12):1741–1764.
   PubMed Web of Science ®Google Scholar
• **Gorgojo-Martinez JJ, Basagoiti-Carreno B, Sanz-Velasco A, et al., Effectiveness and tolerability of orlistat and liraglutide in patients with obesity in a real-world setting: the XENSOR Study. Int J Clin Pract. 2019;73(11):e13399.
   PubMed Web of Science ®Google Scholar
• Wharton S, Liu A, Pakseresht A, et al. Real-World Clinical Effectiveness of Liraglutide 3.0 mg for weight management in Canada. Obesity (Silver Spring). 2019;27(6):917–924.
   PubMed Web of Science ®Google Scholar
• Ganguly R, Tian Y, Kong SX, et al. Persistence of newer anti-obesity medications in a real-world setting. Diabetes Res Clin Pract. 2018;143348–143356.
   Web of Science ®Google Scholar
• Wharton S, Haase CL, Kamran E, et al. Weight loss and persistence with liraglutide 3.0 mg by obesity class in the real-world effectiveness study in Canada. Obes Sci Pract. 2020;6(4):439–444.
   PubMed Web of Science ®Google Scholar
• Nauck MA, Jensen TJ, Rosenkilde C, et al. Neoplasms reported with liraglutide or placebo in people with type 2 diabetes: results from the LEADER randomized trial. Diabetes Care. 2018;41(8):1663–1671.
   PubMed Web of Science ®Google Scholar
• Patel DK, Stanford FC. Safety and tolerability of new-generation anti-obesity medications: a narrative review. Postgrad Med. 2018;130(2):173–182.
   PubMed Web of Science ®Google Scholar
• Ryder R, Thong K, Blann A, et al. Liraglutide pancreatitis: the ABCD nationwide liraglutide audit. Br J Diabetes Vasc Dis. 2013;13(5-6):253-259.
   Google Scholar
• Davies MJ, Aronne LJ, Caterson ID, et al. Liraglutide and cardiovascular outcomes in adults with overweight or obesity: a post hoc analysis from SCALE randomized controlled trials. Diabetes Obes Metab. 2018;20(3):734–739.
   PubMed Web of Science ®Google Scholar
• Marso SP, Daniels GH, Brown-Frandsen K, et al. Liraglutide and cardiovascular outcomes in type 2 diabetes. N Engl J Med. 2016;375(4):311–322.
   PubMed Web of Science ®Google Scholar
• Food and Drug Administration. FDA approves weight management drug for patients aged 12 and older 2020 [cited 2021 Jun 30]. Available from: https://www.fda.gov/drugs/drug-safety-and-availability/fda-approves-weight-management-drug-patients-aged-12-and-older
   Google Scholar
• Kelly AS, Auerbach P, Barrientos-Perez M, et al. A randomized, controlled trial of liraglutide for adolescents with obesity. N Engl J Med. 2020;382(22):2117–2128.
   PubMed Web of Science ®Google Scholar
• Unger JR, Parkin CG. Glucagon-like peptide-1 (GLP-1) receptor agonists: differentiating the new medications. Diabetes Ther. 2011;2(1):29–39.
   PubMedGoogle Scholar
• Ross SA. Breaking down patient and physician barriers to optimize glycemic control in type 2 diabetes. Am J Med. 2013;126(9 Suppl 1):S38–48.
   PubMed Web of Science ®Google Scholar
• Novo Nordisk. SAXENDA (liraglutide [rDNA origin] injection) solution for subcutaneous use prescribing information. Plainsboro, NJ: Novo Nordisk Inc. 2014. [cited 2021 Jun 30]. Available from: http://www.accessdata.fda.gov/drugsatfda_docs/label/2014/206321Orig1s000lbl.pdf
   Google Scholar
• Novo Nordisk. Novo Nordisk needles 2020 [2020 Mar 16th]. Available from: https://www.novoneedles.com
   Google Scholar
• Centers for Disease Control and Prevention. Advancing team-based care through collaborative practice agreements: a resource and implementation guide for adding pharmacists to the care team 2017. [cited 2021 Jun 30]. Available from: https://www.cdc.gov/dhdsp/pubs/docs/CPA-Team-Based-Care.pdf
   Google Scholar
• Centers for Disease Control and Prevention. Pharmacy: collaborative practice agreements to enable collaborative drug therapy management 2017. [cited 2021 Jun 30]. Available from: https://www.cdc.gov/dhdsp/pubs/docs/Best_Practice_Guide_CDTM_508.pdf
   Google Scholar
• Tronieri JS, Wadden TA, Walsh O, et al. Measures of adherence as predictors of early and total weight loss with intensive behavioral therapy for obesity combined with liraglutide 3.0mg. Behav Res Ther. 2020;131:103639.
   PubMed Web of Science ®Google Scholar
• Sharma AM. M, M, M & M: a mnemonic for assessing obesity. Obes Rev. 2010;11(11):808–809.
   PubMed Web of Science ®Google Scholar
• Food and Drug Administration. FDA approves new drug treatment for chronic weight management, first since 2014 2021. [ cited 2021 09 June]: https://www.fda.gov/news-events/press-announcements/fda-approves-new-drug-treatment-chronic-weight-management-first-2014
   Google Scholar
• Lau J, Bloch P, Schaffer L, et al. Discovery of the Once-Weekly glucagon-like peptide-1 (GLP-1) Analogue Semaglutide. J Med Chem. 2015;58(18):7370–7380.
   PubMed Web of Science ®Google Scholar
• Blundell J, Finlayson G, Axelsen M, et al. Effects of once-weekly semaglutide on appetite, energy intake, control of eating, food preference and body weight in subjects with obesity. Diabetes Obes Metab. 2017;19(9):1242–1251.
   PubMed Web of Science ®Google Scholar
• Capehorn MS, Catarig AM, Furberg JK, et al. Efficacy and safety of once-weekly semaglutide 1.0 mg vs once-daily liraglutide 1.2 mg as add-on to 1-3 oral antidiabetic drugs in subjects with type 2 diabetes (SUSTAIN 10). Diabetes Metab. 2019;46(2):100–109.
   PubMed Web of Science ®Google Scholar
• O’Neil PM, Birkenfeld AL, McGowan B, et al. Efficacy and safety of semaglutide compared with liraglutide and placebo for weight loss in patients with obesity: a randomised, double-blind, placebo and active controlled, dose-ranging, phase 2 trial. Lancet. 2018;392(10148):637–649.
   PubMed Web of Science ®Google Scholar
• Wilding JPH, Batterham RL, Calanna S, et al. Once-Weekly semaglutide in adults with overweight or obesity. N Engl J Med. 2021;384(11):989.
   PubMed Web of Science ®Google Scholar
• Wadden TA, Bailey TS, Billings LK, et al. Effect of subcutaneous semaglutide vs placebo as an adjunct to intensive behavioral therapy on body weight in adults with overweight or obesity: the STEP 3 randomized clinical trial. JAMA. 2021;325(14):1403–1413.
   PubMed Web of Science ®Google Scholar
• Rubino D, Abrahamsson N, Davies M, et al. Effect of continued weekly subcutaneous semaglutide vs Placebo on weight loss maintenance in adults with overweight or obesity: the step 4 randomized clinical trial. JAMA. 2021;325(14):1414–1425.
   PubMed Web of Science ®Google Scholar
• Davies M, Faerch L, Jeppesen OK, et al. Semaglutide 2.4 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2): a randomised, double-blind, double-dummy, placebo-controlled, phase 3 trial. Lancet. 2021;397(10278):971–984.
   PubMed Web of Science ®Google Scholar
• Frias JP, Nauck MA, Van J, et al. Efficacy and safety of LY3298176, a novel dual GIP and GLP-1 receptor agonist, in patients with type 2 diabetes: a randomised, placebo-controlled and active comparator-controlled phase 2 trial. Lancet. 2018;392(10160):2180–2193.
   PubMed Web of Science ®Google Scholar
• Thomas MK, Nikooienejad A, Bray R, et al. Dual GIP and GLP-1 receptor agonist tirzepatide improves beta-cell function and insulin sensitivity in type 2 diabetes. J Clin Endocrinol Metab. 2021;106(2):388–396.
   PubMed Web of Science ®Google Scholar
• Del Prato S, Kang J, Trautmann ME, et al. Efficacy and safety of once-monthly efpeglenatide in patients with type 2 diabetes: results of a phase 2 placebo-controlled, 16-week randomized dose-finding study. Diabetes Obes Metab. 2020;22(7):1176–1186.
   PubMed Web of Science ®Google Scholar
• Lee YH, Lee HW, Hj C. GLP-1 based combination therapy for obesity and diabetes. J Obes Metab Syndr. 2017;26(3):155–160.
   PubMed Web of Science ®Google Scholar
• Liberini CG, Koch-Laskowski K, Shaulson E, et al. Combined amylin/GLP-1 pharmacotherapy to promote and sustain long-lasting weight loss. Sci Rep. 2019;9(1):8447.
   PubMedGoogle Scholar